Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
PMID: 31330378
2020
Journal of global antimicrobial resistance
Abstract: Before INSTI treatment one patient harboured the major INSTI-RM R263K and three patients the accessory INSTI-RMs T97A.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
PMID: 32675772
2020
Journal of acquired immune deficiency syndromes (1999)
Abstract: Participants with screening HIV-1 RNA <50 copies/mL for >=6 months; no prior virologic failure; and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1:1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 (early-switch group) or to continue their current antiretroviral regimen and, if virologically suppressed at week 48, switch to dolutegravir plus rilpivirine at week 52 (late-switch group) until week 148.
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
PMID: 30753573
2019
The Journal of antimicrobial chemotherapy
Abstract: INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
PMID: 30648124
2019
Open forum infectious diseases
Abstract: The integrase mutation R263K has been observed in tissue culture experiments and in patients treated with dolutegravir monotherapy in clinical trials.
Abstract: We describe the first
Conclusion: R263K was confirmed by next-generation sequencing (NGS) using an analysis percentage minority variant threshold of >20%.
Conclusion: Follow-up NGS sequencing 3 months after the first resistance test showed the R263K mutation at <5% in a sample with a VL of 61 000 copies/mL.
Conclusion: Poor engagement continued for 18 months; at this later, time integrase resistance testing showed the R263K mutation conferring low-level resistance to DTG and raltegravir, with intermediate resistance to elvitegravir.
Table: R263K
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Discussion: Of note, in our survey, R263K signature mutation that affects the efficacy of DTG was not observed.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary INSTI resistance (-R) substitutions were T66I/A/K, E92Q/G, T97A, F121Y, Y143R/H/C, S147G, Q148H/K/R, N155H/S and R263K in IN.
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
PMID: 31169022
2019
AIDS research and human retroviruses
Abstract: Prevalence of elvitegravir-associated DRMs T66A/I/K, E92Q, S147G, and the dolutegravir-associated DRM R263K increased.
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Result: This residue is involved in resistance to DTG when bearing the M50I mutation in combination with R263K and is selected in vitro by DTG treatment.
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Method: Additionally, if the M50I/R263K mutation was present, we termed it as intermediate resistance to BIC.
Discussion: A selection of R263K/M50I has been described in virus outgrowth assay for BIC that resulted 2.8-fold reduction of BIC-susceptibility, but M50I alone did not have any effect.
Discussion: In breakthrough selections, M50I emerges after R263K and provides replication advantage to R263K containing virus.
Discussion: Mutation R263K mutation has been shown to confer 2- to 5-fold resistance to DTG, with decreased viral replication and strand transfer activity.
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.
PMID: 29617822
2018
The Journal of infectious diseases
Abstract: INSTI-RAMs (S230R, R263K, N155H, and E92Q+N155H) were detected in 4 patients, no INSTI-RAMs were detected in 4 patients, and sequencing of the integrase gene was unsuccessful in 2 patients.
HIV mutation literature information.
PMID: 
2020
Journal of global antimicrobial resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT